Literature DB >> 8438716

Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: the Framingham Study.

L A Cupples1, D R Gagnon, N D Wong, A M Ostfeld, W B Kannel.   

Abstract

Preexisting cardiovascular conditions (angina pectoris, intermittent claudication, stroke or transient ischemic attack, and congestive heart failure) were evaluated in relation to long-term prognosis after an initial MI in 828 subjects from the Framingham Heart Study. Preexisting angina pectoris and intermittent claudication in men were associated with increased risk of coronary mortality and recurrent MI, whereas congestive heart failure increased coronary mortality. In women, prior angina pectoris increased the risk of recurrent MI and congestive heart failure increased the coronary mortality. Adjusting for the major cardiovascular risk factors measured before MI, these results held for men but no significant adverse effects persisted in women. Among subjects who survived to return for subsequent examinations, only prior congestive heart failure in men increased the risk after adjusting for post-MI risk factors. In women who returned, angina pectoris and intermittent claudication were associated with poor post-MI prognosis. These results suggest that atherosclerosis is a diffuse disease of the circulatory system, and one in which post-MI prognosis is influenced by the presence of other preexisting cardiovascular conditions. Hence a patient who has an MI after prior expression of cardiovascular disease requires more vigorous preventive management.

Entities:  

Mesh:

Year:  1993        PMID: 8438716     DOI: 10.1016/0002-8703(93)90182-9

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

1.  Necessity of using intermediate outcome to proxy long term effects. The example of thrombolytics.

Authors:  J S Schwartz
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

Review 2.  Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition.

Authors:  Paul D Rosenblit
Journal:  Curr Diab Rep       Date:  2019-07-22       Impact factor: 4.810

3.  Prevalence of asteroid hyalosis and systemic risk factors in United States adults.

Authors:  Ryan Duong; Xiaoyu Cai; Naveen Ambati; Yevgeniy Shildkrot; Rebecca Sieburth
Journal:  Eye (Lond)       Date:  2022-08-29       Impact factor: 4.456

4.  The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.

Authors:  Alain J Nordmann; Murray Krahn; Alexander G Logan; Gary Naglie; Allan S Detsky
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

5.  A Long-Term Incidence of Heart Failure and Predictors Following Newly Developed Acute Myocardial Infarction: A 10 Years Retrospective Cohort Study with Korean National Health Insurance Data.

Authors:  Hyojung Choi; Joo Yeon Seo; Jinho Shin; Bo Youl Choi; Yu-Mi Kim
Journal:  Int J Environ Res Public Health       Date:  2021-06-08       Impact factor: 3.390

6.  Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events.

Authors:  Benoît Paulmier; Michèle Duet; Raphaël Khayat; Nadia Pierquet-Ghazzar; Jean-Pierre Laissy; Christophe Maunoury; Florent Hugonnet; Elisabeth Sauvaget; Ludovic Trinquart; Marc Faraggi
Journal:  J Nucl Cardiol       Date:  2008 Mar-Apr       Impact factor: 3.872

7.  Assessing the Validity of the Criteria for the Extreme Risk Category of Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Study.

Authors:  Kyung-Soo Kim; Sangmo Hong; Kyungdo Han; Cheol-Young Park
Journal:  J Lipid Atheroscler       Date:  2021-08-18

8.  Type and timing of heralding in ST-elevation and non-ST-elevation myocardial infarction: an analysis of prospectively collected electronic healthcare records linked to the national registry of acute coronary syndromes.

Authors:  Emily Herrett; Julie George; Spiros Denaxas; Krishnan Bhaskaran; Adam Timmis; Harry Hemingway; Liam Smeeth
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.